Fresenius Medical Care AG (ETR:FME)
Germany
· Delayed Price · Currency is EUR | Market Cap | 13.51B |
| Revenue (ttm) | 19.34B |
| Net Income (ttm) | 537.91M |
| Shares Out | 293.41M |
| EPS (ttm) | 1.83 |
| PE Ratio | 25.16 |
| Forward PE | 12.83 |
| Dividend | 1.44 (3.13%) |
| Ex-Dividend Date | May 23, 2025 |
| Volume | 507,451 |
| Average Volume | 636,371 |
| Open | 45.80 |
| Previous Close | 46.04 |
| Day's Range | 45.80 - 48.80 |
| 52-Week Range | 32.51 - 48.80 |
| Beta | 0.83 |
| RSI | 67.57 |
| Earnings Date | May 6, 2025 |
About Fresenius Medical Care AG
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the United States for the hospital... [Read more]
Financial Performance
In 2024, Fresenius Medical Care AG's revenue was 19.34 billion, a decrease of -0.61% compared to the previous year's 19.45 billion. Earnings were 537.91 million, an increase of 7.80%.
Financial StatementsNews
Fresenius Medical Care Non-GAAP EPS of €0.84, revenue of €4.88B; reaffirms FY25 outlook
Fresenius Medical Care starts 2025 with strong organic revenue and income growth
Strong organic revenue growth1 of 5% driven by Care Enablement and Care Delivery Stable U.S. same market treatment development despite impact from a severe flu season FME25 savings of EUR 68 million c...
Fresenius Medical Care tops market expectations in 1st quarter
World's largest dialysis specialist Fresenius Medical Care reported first-quarter results above analysts' expectations on Tuesday, as revenue grew organically in all its segments, it said.
Fresenius Medical Care: Why I'm Not (Yet) Biting Despite Turnaround Progress
Investigating Privia Health Gr's Standing In Health Care Providers & Services Industry Compared To Competitors
In the dynamic and fiercely competitive business environment, conducting a thorough analysis of companies is crucial for investors and industry enthusiasts. In this article, we will perform an extensi...
EQS-PVR: Fresenius Medical Care AG: Correction of a release from 10/04/2025 according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Fresenius Medical Care AG Fresenius Medical Care AG: Correction of a release from 10/04/2025 according to Article 40, Section 1 of the WpHG [the German Securities Tradi...
BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks
Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.
EQS-PVR: Fresenius Medical Care AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Fresenius Medical Care AG Fresenius Medical Care AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Eu...
EQS-DD: Fresenius Medical Care AG: Dr. Katarzyna Mazur-Hofsäß, Acquisition of shares under the Fresenius Medical Care Management Board Long Term Incentive Plan 2020 (Allocation 2022)
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 19.03.2025 / 09:50 CET/CEST The issuer is solely responsi...
EQS-DD: Fresenius Medical Care AG: Franklin W. Maddux, Acquisition of shares under the Fresenius Medical Care Management Board Long Term Incentive Plan 2020 (Allocation 2022)
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 19.03.2025 / 09:48 CET/CEST The issuer is solely responsi...
EQS-DD: Fresenius Medical Care AG: Helen Pring Giza, Acquisition of shares under the Fresenius Medical Care Management Board Long Term Incentive Plan 2020 (Allocation 2022)
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 19.03.2025 / 09:47 CET/CEST The issuer is solely responsi...
Fresenius Medical Care publishes its joint Annual Report and Sustainability Statement for 2024: Building the Momentum
In 2024, the operating model to deliver the highest quality of patient care was further optimized by enhancing financial returns, and creating value for shareholders Fresenius Medical Care delivered 1...
Fresenius Medical Care AG (FMS) Trading Down 3.52% on Mar 4
Fresenius Medical Care AG (FMS) Trading Down 3.52% on Mar 4
Fresenius Medical Care's stock falls on Fresenius' stake sale
Dialysis firm Fresenius Medical Care shares fell 7.8% after German healthcare group Fresenius SE sold part of its stake in the company.
Fresenius Sells Fresenius Medical Care Stake For $1.15 Billion
The healthcare group said the proceeds will help strengthen its balance sheet and reduce leverage
EQS-Adhoc: Fresenius SE & Co. KGaA: Fresenius announces its intention to reduce its stake in Fresenius Medical Care AG from currently around 32.2% to no less than 25% plus one share
EQS-Ad-hoc: Fresenius SE & Co. KGaA / Key word(s): Investment Fresenius SE & Co. KGaA: Fresenius announces its intention to reduce its stake in Fresenius Medical Care AG from currently around 32.2% to...
Fresenius Medical Care AG (FMS) Q4 2024 Earnings Conference Call Transcript
Fresenius Medical Care AG (FMS) Reports Strong Earnings Growth and Strategic Progress in 2024
Fresenius Medical Care AG (FMS) Reports Strong Earnings Growth and Strategic Progress in 2024
Fresenius Medical Care's first ever tariff taskforce looking at potential tariffs on medical equipment, says CEO
Helen Giza, the CEO of Fresenius Medical Care, discusses the German healthcare company's latest earnings and its new tariff task force.
Fresenius Medical Care delivers 18% earnings growth in 2024 and continues the acceleration momentum into 2025
Organic revenue growth1 of 4% driven by Care Enablement and Care Delivery Underlying U.S. same market treatment growth further accelerated in Q4 and turned positive for the full year Accumulated savin...
Fresenius Medical Care AG (FMS) Announces Divestment of Select Laboratory Assets to Quest ...
Fresenius Medical Care AG (FMS) Announces Divestment of Select Laboratory Assets to Quest Diagnostics
Fresenius Medical Care Narrows Key Earnings Metric View on Profit Slump
Fresenius Medical Care slightly beats market estimates in fourth quarter
Fresenius Medical Care , the world's largest dialysis specialist, reported fourth quarter results slightly above market expectations on Tuesday, citing positive development both in its care delivery a...
Fresenius Medical Care Announces Divestment of Select Laboratory Assets to Quest Diagnostics
Quest to provide comprehensive dialysis-related laboratory and water testing services to Fresenius Medical Care owned and affiliated clinics in the United States BAD HOMBURG, Germany and SECAUCUS, N.J...
Fresenius Medical Care: A 'Buy' Going Into 2025
Fresenius Medical Care has seen 18.5% growth, with strong prospects. Learn why FMS stock’s fair value of $34/share makes it a solid “Buy” opportunity.